MTOR and neoplasm: Interestingly, activation of the PI3K/AKT/mTOR pathway is involved in resistance to Shh inhibitors (42) and in proliferation and survival of tumor stem cells (43, 44), thus contributing to the very poor prognosis of the high-risk patients.